| scholarly article | Q13442814 |
| P50 | author | Lewis Kuller | Q88077314 |
| P2093 | author name string | James D Neaton | |
| Multiple Risk Factor Intervention Trial Research Group | |||
| Jerome D Cohen | |||
| Ronald Prineas | |||
| Gregory Grandits | |||
| P2860 | cites work | Effect of obesity on the relationship between plasma C-reactive protein and coronary artery stenosis in patients with stable angina | Q80384257 |
| Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population | Q81103628 | ||
| Fat, fit, and leading the charge: the evolution of measuring high-density lipoprotein subpopulations | Q81299166 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. | Q34588530 | ||
| Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans | Q35559092 | ||
| High-density lipoprotein subfractions and risk of coronary artery disease | Q35856884 | ||
| ATP-binding cassette transporter AI and its role in HDL formation | Q36009483 | ||
| Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease | Q36095122 | ||
| Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance | Q36169943 | ||
| Structural modifications of HDL and functional consequences | Q36255533 | ||
| Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport | Q36408224 | ||
| Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds | Q36424501 | ||
| Quality control of biochemical data in the Multiple Risk Factor Intervention Trial: Central Laboratory | Q36482119 | ||
| LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). | Q40317506 | ||
| Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women | Q40400158 | ||
| Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women | Q40628500 | ||
| Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study | Q43748428 | ||
| Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial | Q44054640 | ||
| Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study | Q44063976 | ||
| Association between dietary factors and plasma adiponectin concentrations in men. | Q44264871 | ||
| Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. | Q44398229 | ||
| Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 Diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study | Q44438940 | ||
| Plasma adiponectin levels and risk of myocardial infarction in men. | Q44843420 | ||
| The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. | Q45199710 | ||
| Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial | Q45332825 | ||
| Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial | Q45333030 | ||
| Cardioprotective effects of high-density lipoproteins: the evidence strengthens | Q46568429 | ||
| Ability of serum to decrease cellular acylCoA:cholesterol acyl transferase activity predicts cardiovascular outcomes | Q46757559 | ||
| Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial | Q46865016 | ||
| Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study | Q46870294 | ||
| Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study | Q47705728 | ||
| Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease | Q47810201 | ||
| Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer | Q47985829 | ||
| The multiple risk factor intervention trial (MRFIT). III. The model for intervention | Q49122085 | ||
| Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. | Q51597227 | ||
| Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. | Q52454638 | ||
| Recruitment of participants for the multiple risk factor intervention trial (MRFIT) | Q68681148 | ||
| Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group | Q69884095 | ||
| Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group | Q70255536 | ||
| An evaluation of the Social Security Administration master beneficiary record file and the National Death Index in the ascertainment of vital status | Q71058071 | ||
| Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial | Q71512983 | ||
| Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial | Q73832888 | ||
| Association of hypoadiponectinemia with coronary artery disease in men | Q78780687 | ||
| Does the metabolic syndrome exist? | Q79793016 | ||
| P433 | issue | 1 | |
| P921 | main subject | heart disease | Q190805 |
| metabolic syndrome | Q657193 | ||
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 122-128 | |
| P577 | publication date | 2006-10-02 | |
| P1433 | published in | Atherosclerosis | Q4813570 |
| P1476 | title | Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome | |
| P478 | volume | 195 |
| Q34562731 | A lack of association between adiponectin polymorphisms and coronary artery disease in a Chinese population |
| Q47642328 | Adiponectin circulating levels and 10-year (2002-2012) cardiovascular disease incidence: the ATTICA Study. |
| Q35468728 | Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans |
| Q37372502 | Associations of adiponectin and leptin with incident coronary heart disease and ischemic stroke in african americans: the jackson heart study |
| Q79859560 | Can we learn more about the etiology of cardiovascular disease? |
| Q38377434 | Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). |
| Q37440932 | Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy |
| Q40764452 | Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic S |
| Q26779287 | HDL particle number and size as predictors of cardiovascular disease |
| Q38214018 | HDL-targeted therapies: progress, failures and future |
| Q34712485 | HIV/hepatitis C virus coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infection |
| Q36141889 | High-Density Lipoprotein Subclasses and Noncardiovascular, Noncancer Chronic Inflammatory-Related Events Versus Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis |
| Q36139932 | High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). |
| Q91615213 | High-density lipoprotein cholesterol efflux capacity is not associated with atherosclerosis and prevalence of cardiovascular outcome: The CODAM study |
| Q37254454 | High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy |
| Q33737098 | High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease |
| Q33556997 | High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection |
| Q46559839 | Histopathologic findings associated with APOL1 risk variants in chronic kidney disease |
| Q37409448 | Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk |
| Q36433627 | Lipoprotein Particles in Adolescents and Young Women With PCOS Provide Insights Into Their Cardiovascular Risk |
| Q33639078 | Lipoprotein particle subclasses, cardiovascular disease and HIV infection. |
| Q35221749 | Lipoprotein particles and size, total and high molecular weight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: The Women's Health Initiative Observational Study |
| Q28086787 | Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct? |
| Q36819477 | Physical activity and coronary artery calcification in two cohorts of women representing early and late postmenopause |
| Q35501308 | Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women |
| Q55489555 | Relation between high density lipoprotein particles concentration and cardiovascular events: a meta-analysis. |
| Q38221965 | Role of HDL in those with diabetes |
| Q95326868 | Serum level of HDL particles are independently associated with long-term prognosis in patients with coronary artery disease: The GENES study |
| Q36926879 | Superiority of lipoprotein particle number to detect associations with arterial thickness and stiffness in obese youth with and without prediabetes. |
| Q37435503 | Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. |
| Q35658743 | Target organ damage in African American hypertension: role of APOL1. |
| Q53756954 | The association between HDL particle concentration and incident metabolic syndrome in the multi-ethnic Dallas Heart Study. |
| Q36328349 | The effects of exercise on the lipoprotein subclass profile: A meta-analysis of 10 interventions |
| Q34513438 | The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective |
| Q100311831 | Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk |
| Q38363617 | Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy |
Search more.